Description

Clinical or preclinical evidence summary for probiotic-fermented herbal therapeutics in T2DM management. Glucose metabolism, insulin sensitivity, and beta-cell function endpoints are reviewed across studies.

Figure 8

Diagram

Source Paper

Gut Microbiota-Targeted Therapeutics for Metabolic Disorders: Mechanistic Insights into the Synergy of Probiotic-Fermented Herbal Bioactives.

International journal of molecular sciences (2025)

PMID: 40564947

DOI: 10.3390/ijms26125486

Cite This Figure

![Figure 8: Clinical or preclinical evidence summary for probiotic-fermented herbal therapeutics in T2DM management. Glucose metabolism, insulin sensitivity, and beta-cell function endpoints are reviewed across studies.]()

> Source: Yue Fan et al. "Gut Microbiota-Targeted Therapeutics for Metabolic Disorders: Mechanistic Insigh." *International journal of molecular sciences*, 2025. PMID: [40564947](https://pubmed.ncbi.nlm.nih.gov/40564947/)

<figure>
  <img src="" alt="Clinical or preclinical evidence summary for probiotic-fermented herbal therapeutics in T2DM management. Glucose metabolism, insulin sensitivity, and beta-cell function endpoints are reviewed across studies." />
  <figcaption>Figure 8. Clinical or preclinical evidence summary for probiotic-fermented herbal therapeutics in T2DM management. Glucose metabolism, insulin sensitivity, and beta-cell function endpoints are reviewed across studies.<br>  Source: Yue Fan et al. "Gut Microbiota-Targeted Therapeutics for Metabolic Disorders: Mechanistic Insigh." <em>International journal of molecular sciences</em>, 2025. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40564947/">40564947</a></figcaption>
</figure>

Preuves associées

Berberine pour Gut Dysbiosis

Note D · 2 études